EichorEICHOR
Condition: Transitional Cell Carcinoma Of Renal Pelvis Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Transitional Cell Carcinoma Of Renal Pelvis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
Phase 2/Phase 3 · 8 location(s) · Peter Black · NCT061249769MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06823427Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/
Phase N/A · 1 location(s) · University of Washington · NCT01050504Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
Phase 2 · 1 location(s) · Nagoya University · NCT06983210A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and U
NA · 1 location(s) · University of Washington · NCT06040762Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · 499 location(s) · National Cancer Institute (NCI) · NCT05987241Bladder EpiCheck European Haematuria Study
Phase N/A · 5 location(s) · Nucleix Ltd. · NCT06818136Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma
NA · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07630155Radical Radiotherapy Versus Radical Surgery for UTUC
Phase N/A · 2 location(s) · Peking University First Hospital · NCT06652009Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Phase 1/Phase 2 · 9 location(s) · Ferring Pharmaceuticals · NCT06668493FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Phase 1 · 82 location(s) · Eli Lilly and Company · NCT05614739A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Phase 1 · 39 location(s) · Eli Lilly and Company · NCT06465069Sacituzumab Govitecan Plus EV in Metastatic UC
Phase 1/Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT04724018Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Phase 2 · 1 location(s) · Mayo Clinic · NCT07087860uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Phase N/A · 22 location(s) · UroGen Pharma Ltd. · NCT05874921Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
Phase 3 · 1 location(s) · University of Texas Southwestern Medical Center · NCT04865939Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary
Phase 2/Phase 3 · 257 location(s) · National Cancer Institute (NCI) · NCT04628767
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.